Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

I. a. Pneumococcus polysaccharides, when injected intradermally into patients convalescent from pneumonia, are capable of eliciting a response. The polysaccharide inducing a cutaneous reaction was found always to be homologous in type to that of the pneumococcus causing the infection. b. The character of the reaction incited by the protein-free bacterial sugars is of the immediate wheal and erythema type. c. A patient's capacity to react was found to be intimately associated both with recovery from infection and with the presence of type specific antibodies in the circulating blood. II. a. The so-called nucleo-protein of pneumococcus, when injected intradermally, also causes a local cutaneous reaction in patients during convalescence from lobar pneumonia. b. The local lesion resulting from the injection of protein is tuberculin-like in character, and differs from that evoked by the type-specific polysaccharides in gross appearance, time of development, and duration. c. Individuals, acutely ill with and convalescent from pneumococcus pneumonia, possess in their circulating blood, precipitins reactive with pneumococcus protein. In the observations recorded, the concentration of anti-protein antibodies in the blood serum did not seem to influence the patient's capacity to react to intradermal injection of the protein.
 ...
PMID:CUTANEOUS REACTIONS TO THE POLYSACCHARIDES AND PROTEINS OF PNEUMOCOCCUS IN LOBAR PNEUMONIA. 1986 55

The majority of patients convalescent from pneumonia due to Types I, II and III Pneumococcus develop at the time of recovery circulating antibodies for the homologous type of organisms. At the same time an immediate wheal and erythema reaction followed the intradermal injection of the homologous type-specific polysaccharide in 100 per cent of Type I patients, 58.8 per cent of Type II patients, and 44 per cent of Type III patients. In a group of 18 patients repeatedly tested with the type-specific polysaccharides, 10 developed in the second or third week of convalescence circulating antibodies for one or more heterologous types. In none of 21 control patients was this phenomenon observed. It is suggested that the development of circulating antibodies for heterologous types of Pneumococcus was associated with the previous intradermal injections of the type-specific polysaccharides.
 ...
PMID:CUTANEOUS REACTIONS IN PNEUMONIA. THE DEVELOPMENT OF ANTIBODIES FOLLOWING THE INTRADERMAL INJECTION OF TYPE-SPECIFIC POLYSACCHARIDE. 1986 89

A study of 46 cases of pneumococcus pneumonia has shown that a characteristic response may be elicited by the intracutaneous injection of 0.1 mg. of the somatic C polysaccharide of pneumococcus. During the acute febrile period in patients who recover, the response consists of a delayed erythema which reaches its maximum intensity in 18 to 24 hours. During convalescence the reaction is not demonstrable. In patients in whom the disease is prolonged by complications the capacity of the skin to react persists. In 7 fatal cases the skin failed to react to C polysaccharide. Parallel studies of the reaction of the patients' serum with C have confirmed and extended the observations of Tillett and Francis on the appearance of the precipitation phenomenon during the acute stages and its disappearance in recovery. That the cutaneous and serological reactions are not specific for pneumococcus infection is shown by the results in 29 control cases. 8 patients with infectious febrile diseases not of pneumococcus origin gave responses similar to those noted in pneumonia. 2 patients with non-infectious fevers and 18 of 19 normal individuals failed to give either skin or serum reactions. These observations emphasize the importance of using separate components of the bacterial cell in the interpretation of cutaneous and serological reactions in pneumonia. The parallelism in results of the skin and serum tests in pneumococcus pneumonia with the somatic carbohydrate C, the significance of the reactions in relation to the clinical course and outcome of the disease, and the frequency of occurrence of both reactions in bacterial infections other than those of pneumococcal origin, are discussed.
 ...
PMID:STUDIES ON THE SOMATIC C POLYSACCHARIDE OF PNEUMOCOCCUS : I. CUTANEOUS AND SEROLOGICAL REACTIONS IN PNEUMONIA. 1987 May 91

We report a complication of the novel H1N1 influenza A viral infection not yet described during this 2007-2009 pandemic. Pulmonary hemorrhage is a known complication of influenza pneumonia, including well documented reports from previous pandemics. A 57-year-old African American female presented with fevers, progressive shortness of breath, and cough. After being admitted with an initial diagnosis of myocardial infarction, hemoptysis developed. Nasopharyngeal swabs rapid testing was negative for influenza A and B antigen, but a polymerase chain reaction test for influenza A type H1N1 was positive. A fiberoptic bronchoscopy for ongoing hemoptysis demonstrated diffuse erythema and bleeding, and bronchoalveolar lavage was consistent with alveolar hemorrhage. Progressive hypoxemic respiratory failure ensued, eventually leading to her demise. Our case highlights one of the more feared complications that may have been more common in prior outbreaks, such as the 1918 "Spanish Flu." Autopsy studies from the 1918 influenza pandemic found severe tracheobronchitis (oftentimes hemorrhagic), septal edema, necrotizing bronchiolitis, alveolitis, and extensive hemorrhage, as opposed to the more benign laryngitis and tracheobronchitis that is commonplace in other influenza infections. Similar pathology appearances, including pulmonary hemorrhage, have also been described in H5N1 outbreaks in China and Thailand. It is crucial for pandemic preparedness planning that additional careful and complete autopsy study of this present pandemic influenza infection be performed and reported to answer questions regarding the natural history, pathology, and pathogenesis of this novel H1N1 influenza.
 ...
PMID:Novel H1N1 influenza A viral infection complicated by alveolar hemorrhage. 2042 Jul 34

: A 59-year-old man was admitted to the hospital with pulmonary infiltration, fever, erythema, and eosinophilia. Two weeks before admission, he received amoxicillin, acetaminophen, and shoseiryu-to (a Japanese herbal medicine) for a common cold. Bronchoalveolar lavage was performed, and an increased number of eosinophils was recovered. Transbronchial biopsy specimens showed granuloma and interstitial thickening with eosinophils and lymphocytes. Drug-induced eosinophilic pneumonia was suspected, so all drugs were discontinued. The symptoms and infiltration shadow disappeared. A drug-induced lymphocyte stimulation test (DLST) was positive for acetaminophen but not for amoxicillin. In contrast to the DLST, a provocation test revealed that amoxicillin induced the drug allergy. A very striking observation was the coexistence of pulmonary eosinophilia and granulomatous lung infiltrations. In addition, there was a discrepancy between the DLST and provocation test findings. To our knowledge, there is no previous report of drug-induced eosinophilic pneumonia with a granulomatous reaction.
 ...
PMID:Amoxicillin-Induced Eosinophilic Pneumonia with Granulomatous Reaction: Discrepancy between Drug-Induced Lymphocyte Stimulation Test Findings and the Provocation Drug Test. 2052 46

Rosacea is a chronic cutaneous disorder characterized by centrofacial persisting erythema, telangiectases, papules, pustules, edema, phymas and ocular involvement. Despite being one of the most common skin disorders, its pathogenesis remains unclear and controversial. Although the disease triggering factors are well recognized, the underlying causes of rosacea have not yet been identified. Several different postulates about its pathogenesis can be found in the medical literature. Abnormalities of the pilosebaceous unit, as well as genetic, vascular, inflammatory, environmental and microbial factors have been described. The microorganisms that have been associated include Helicobacter pylori, Demodex folliculorum, Staphylococcus epidermidis, and Chlamydia pneumonia; all the studies have been inconclusive. We review currently available scientific data on the potential pathogenetic role of microorganisms in the development of rosacea.
 ...
PMID:The potential role of microorganisms in the development of rosacea. 2105 71

Bleomycin is an anti-neoplastic antibiotic used in chemotherapeutic regimens for Hodgkin lymphoma, testicular tumour and Kaposi's sarcoma and to induce chemical pleurodesis in malignant effusions. Bleomycin toxicity predominantly affects the skin and lungs. Skin toxicity classically presents as flagellate erythema, a rare drug rash, where the patient appears to have been whipped. Bleomycin-induced pneumonitis is more commonly recognised and can occasionally prove fatal. Although both these conditions are well documented in the literature, in clinical practice they are uncommon. Indeed, in our institution (a teaching hospital with a large lymphoma practice) we cannot recall a previous case of flagellate erythema. Both skin and lung toxicities induced by bleomycin usually respond to discontinuation of the drug and steroid therapy. We present two case studies of patients with bleomycin-related toxicity and a short synopsis of current literature.
 ...
PMID:Toxicities associated with bleomycin. 2112 62

Voriconazole is an extended-spectrum triazole antifungal approved for treatment of invasive fungal infections. The drug has been associated with phototoxicity, presenting as photodistributed eruptions such as macular erythema or pseudoporphyria. We describe a 59-year-old man with acute myeloid leukemia, status-post matched unrelated donor stem cell transplant, who developed fungal pneumonia and was placed on posaconazole. The patient had difficulty complying with the four-times daily dosing and was switched to voriconazole 200 mg twice daily. Soon after, the patient began working outside and subsequently developed photodistributed, macular erythema of the head, neck, and upper chest. Melanoma and squamous cell carcinoma have developed in patients with chronic treatment with voriconazole. Strict adherence to photoprotective measures can prevent the side effect of phototoxic eruption or prevent recurrence in patients who develop this adverse reaction without having to discontinue voriconazole.
 ...
PMID:Voriconazole-associated phototoxicity. 2138 98

We report two cases of erythema exsudativum multiforme (EEM) that we concluded were caused by infections with Chlamydia pneumoniae. High titers of IgG antibody for Chlamydia pneumoniae were shown in the sera of both cases. One case showed the classical symptoms of pneumonia together with radiological changes in the chest; the other case did not show these symptoms. To the best of our knowledge, only three cases of erythema multiforme associated with Chlamydia pneumoniae infection have been reported.
 ...
PMID:Two cases of erythema exsudativum multiforme associated with Chlamydia pneumoniae infection. 2195 Apr 77

In minor cases, contrast extravasation may cause pain, swelling, and localized erythema. However, in more severe cases, extensive tissue and skin necrosis, ulceration, and compartment syndrome may occur, often necessitating a surgical consultation. Hyaluronidase has been used successfully in the management of extravasated contrast media in several reports. In addition, recombinant human hyaluronidase is approved for use as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. In this case, a 57-year-old white female admitted for a chronic obstructive pulmonary disease exacerbation with pneumonitis and hypoxic respiratory failure experienced contrast extravasation during a computed tomographic scan of her chest. Approximately 100 mL of iodinated contrast extravasated into the right antecubital fossa, infiltrating approximately the distal two-thirds of the upper arm. Five 150-U vials of recombinant human hyaluronidase were injected in 150-U aliquots in a circle around the extravasation site using a 27-gauge needle 1 hour after the extravasation occurred. In a follow-up 4 hours later, marked improvement was observed. Sixteen hours after hyaluronidase treatment, the tissue had reverted to a near-normal state with no pain, erythema, swelling, or tenderness noted. Hyaluronidase successfully treated this extravasation of a large volume of iodinated contrast and appears to be a reasonable treatment option for more extensive subcutaneous contrast media extravasations.
 ...
PMID:Extravasation of contrast media managed with recombinant human hyaluronidase. 2263 26


<< Previous 1 2 3 4 5 6 7 8 Next >>